Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BTG Set To Launch First Radiopaque Drug-Eluting Bead In The EU

Executive Summary

DC Bead Lumi is designed to be loaded with doxorubicin or irinotecan to treat liver cancer while showing the treating physician where it is to improve control of transarterial chemoembolization procedures.

You may also be interested in...



Biocompatibles Settles Charges Of Illegally Selling Device As Drug-Delivery Combo

The company pleaded guilty to a misdemeanor misbranding charge and agreed to pay $11m in criminal penalties and another $25m to resolve civil False Claims Act allegations. Biocompatibles reportedly marketed its LC Bead product as a drug-delivery product, even though it was cleared only for embolization.

OUS Approvals Analysis: Expanded CoreValve Indication And Zika IVDs Among August’s CE Marks

August was another slow month for announcements of medical device approvals outside the US, but the short list of non-US approvals this month includes a broad range of device-types approved, notably a much-awaited expanded indication for Medtronic’s CoreValve Evolut R, in six different territories.

BTG Deals Its Way Into Interventional Medicine

UK-listed BTG PLC is on a route to a major future in interventional medicine, having built solid foundations in licensing and specialty pharma. CEO Louise Makin describes the deal- and decision-making rationale that has allowed a mid-cap player to set billion-dollar plus ambitions in interventional medicine, based on organic and M&A growth.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT104555

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel